Clinical Outcome Following Second-Generation Drug-Eluting Stent Use for Off-Label Versus On-Label Indications: Insights From the Two-Year Outcome of the TWENTE Trial

EuroIntervention - France
doi 10.4244/eijv10i6a117
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Europa Digital & Publishing

Related search

Available Evidence and Outcome of Off-Label Use of Rituximab in Clinical Practice

European Journal of Clinical Pharmacology
MedicinePharmacology
2013English

Reasons for and Frequency of Off - Label Drug Use

Medicinski Pregled
Medicine
2015English

Outcomes and Complications Associated With Off-Label and Untested Use of Drug-Eluting Stents

JAMA - Journal of the American Medical Association
Medicine
2007English

Off-Label Drug Use in Hospitalized Children

Archives of Pediatrics & Adolescent Medicine
2007English

Clinical and Economic Outcomes of Liberal Versus Selective Drug-Eluting Stent Use: Insights From Temporal Analysis of the Multicenter Evaluation of Drug Eluting Stents and Ischemic Events (EVENT) Registry

Circulation
Cardiovascular MedicinePhysiologyCardiology
2011English

First-Generation Versus Second-Generation Drug-Eluting Stents in Coronary Chronic Total Occlusions: Two-Year Results of a Multicenter Registry

PLoS ONE
Multidisciplinary
2016English

«Off Label Use»: Nouvelles Recommandations

Bulletin des Médecins Suisses
2007English

Two-Year Outcome After Biodegradable Polymer Sirolimus- And Biolimus-Eluting Coronary Stents (From the Randomised SORT OUT VII Trial)

EuroIntervention
MedicineCardiovascular MedicineCardiology
2018English

Pmd5 Outcome Study of Drug Eluting Stent (Des) Versus Bare Metal Stent (Bms) in Hong Kong: A 6-Month Pilot Study

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy